Cargando…
Safety and Immunogenicity of a ChAd155-Vectored Respiratory Syncytial Virus (RSV) Vaccine in Healthy RSV-Seropositive Children 12–23 Months of Age
BACKGROUND: Safe and effective respiratory syncytial virus (RSV) vaccines remain elusive. This was a phase I/II trial (NCT02927873) of ChAd155-RSV, an investigational chimpanzee adenovirus-RSV vaccine expressing 3 proteins (fusion, nucleoprotein, and M2-1), administered to 12–23-month-old RSV-seropo...
Autores principales: | Díez-Domingo, Javier, Sáez-Llorens, Xavier, Rodriguez-Weber, Miguel A, Epalza, Cristina, Chatterjee, Archana, Chiu, Cheng-Hsun, Lin, Chien-Yu, Berry, Andrea A, Martinón-Torres, Federico, Baquero-Artigao, Fernando, Langley, Joanne M, Ramos Amador, José T, Domachowske, Joseph B, Huang, Li-Min, Chiu, Nan-Chang, Esposito, Susanna, Moris, Philippe, Lien-Anh Nguyen, Thi, Nikic, Vanja, Woo, Wayne, Zhou, Yingjun, Dieussaert, Ilse, Leach, Amanda, Gonzalez Lopez, Antonio, Vanhoutte, Nicolas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10226655/ https://www.ncbi.nlm.nih.gov/pubmed/36484484 http://dx.doi.org/10.1093/infdis/jiac481 |
Ejemplares similares
-
ChAd155-RSV vaccine is immunogenic and efficacious against bovine RSV infection-induced disease in young calves
por: de Jong, Rineke, et al.
Publicado: (2022) -
First-in-Human Randomized Study to Assess the Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus (RSV) Vaccine Based on Chimpanzee-Adenovirus-155 Viral Vector–Expressing RSV Fusion, Nucleocapsid, and Antitermination Viral Proteins in Healthy Adults
por: Cicconi, Paola, et al.
Publicado: (2020) -
1958. Antiviral Effects, Pharmacokinetics (PK), and Safety of the Respiratory Syncytial Virus (RSV) Fusion Protein Inhibitor, JNJ-53718678 (JNJ-8678), in RSV-infected Infants With Bronchiolitis, in the Phase 1b Study 53718678RSV1005
por: Martinon-Torres, Federico, et al.
Publicado: (2018) -
Pharmacokinetics, Safety, and Antiviral Effects of Multiple Doses of the Respiratory Syncytial Virus (RSV) Fusion Protein Inhibitor, JNJ-53718678, in Infants Hospitalized With RSV Infection: A Randomized Phase 1b Study
por: Martinón-Torres, Federico, et al.
Publicado: (2020) -
Global molecular diversity of RSV – the “INFORM RSV” study
por: Langedijk, Annefleur C., et al.
Publicado: (2020)